Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Institut de Recherche pour le Developpement Global Fund Ministry of Health, Thailand |
---|---|
Information provided by: | Institut de Recherche pour le Developpement |
ClinicalTrials.gov Identifier: | NCT00433030 |
Since 2004, the Thai Ministry of Public Health has massively scaled up antiretroviral treatment programs to provide therapy to more than 80,000 patients with partial support of the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM).
As access to HIV care continues to expand under the universal health coverage system, it is important to document and analyze the efficacy, tolerance, toxicity and acceptability of antiretroviral therapy within pilot treatment programs, to provide evidence based feedback and recommendations to the national program and policy makers.
Condition |
---|
HIV Infections |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Estimated Enrollment: | 2000 |
Study Start Date: | January 2007 |
Estimated Study Completion Date: | November 2008 |
As Thailand is rapidly expanding access to antiretroviral treatments under the universal health coverage system, it is crucial to document and learn from pilot antiretroviral treatment programs, in particular the medical outcomes and logistical, and organizational issues faced by hospital teams and patients in order to adapt the ARV delivery and monitoring system to various local settings.
Specific objectives
The population of the study consists of approximately 2,000 consenting HIV-infected patients, including one-third of children, receiving HIV care as part of the GF-ATM or OXFAM Access to Antiretroviral programs, presenting at any of the PHPT network hospitals.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
HIV-infected Adults and Children
Inclusion Criteria:
Adults and children (children are defined as less than 18 years old) patients are eligible for the inclusion in the cohort if they meet all the following inclusion criteria:
Exclusion Criteria:
Contact: Marc Lallemant, MD | +66 53814633 ext 0 | marc@phpt.org |
Contact: Gonzague Jourdain, MD, PhD | +66 53814633 ext 0 | gonzague@phpt.org |
Principal Investigator: | Marc Lallemant, MD | Institut de Recherche pour le Developpement |
Study ID Numbers: | PHPT-Cohort |
Study First Received: | February 8, 2007 |
Last Updated: | April 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00433030 |
Health Authority: | Thailand: Ministry of Public Health |
Highly Active Antiretroviral Therapy HIV Viral load HIV drug Resistance Thailand |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
RNA Virus Infections Slow Virus Diseases Immune System Diseases Lentivirus Infections Infection |